Cizzle Biotechnology publishes final results for the year ended 31 December 2023

Cizzle Biotechnology Holdings

Cizzle Biotechnology Holdings plc (LON:CIZ), the UK based diagnostics developer, has announced the publication of the Company’s Annual Report and Financial Statements for the year ended 31 December 2023:

Cizzle Biotechnoloy is developing a blood test for the early detection of lung cancer. The Company is a spin- out from the University of York, founded in 2006, around the work of Professor Coverley and colleagues. Its proof-of-concept prototype test is based on the ability to detect a stable plasma biomarker, a variant of CIZ1 known as CIZ1B. CIZ1 is a naturally occurring cell nuclear protein involved in DNA replication, and the targeted CIZ1B variant is highly correlated with early-stage lung cancer.

We’ll keep you in the loop!

Join 1,000's of investors who read our articles first

We don’t spam! Read our privacy policy for more info.

Share on:
Find more news, interviews, share price & company profile here for:

    Cizzle Biotechnology raises £150k to support cancer test rollout

    Cizzle Biotechnology Holdings Plc has raised £150,000 to advance its CIZ1B early cancer test, enhancing access to innovative diagnostics in the UK and Europe.

    Cizzle Bio expands into Caribbean with first contract, secures early royalties

    Cizzle Biotechnology announces significant strides in early lung cancer detection through its partner's first Caribbean contract, boosting its biomarker test rollout.

    Cizzle Biotechnology launches its new corporate website

    Cizzle Biotechnology Holdings plc has launched a new corporate website, enhancing access to vital information about its early cancer tests and growth strategy.

    Cizzle Biotechnology appoints Matt Bower as a Non-Executive Director

    Cizzle Biotechnology appoints Matt Bower as Non-Executive Director, enhancing its board for growth as it prepares to launch innovative cancer tests globally.

    Cizzle Bio appoints iGenomeDX to launch CIZ1B biomarker test in USA

    Cizzle Biotechnology announces a breakthrough in early lung cancer detection with iGenomeDX appointed to launch the CIZ1B biomarker test across the USA.

    Cizzle Biotechnology appoints Professor Dawn Coverley as Chief Scientific Officer

    Cizzle Biotechnology names Professor Dawn Coverley as Chief Scientific Officer, marking a strategic shift. She will focus on advancing the CIZ1B biomarker assay.

      Search

      Search